Slow-wave sleep-promoting factors in brain and urine were identified as muramyl peptides (MPs), the building blocks of bacterial cell wall peptidoglycan. In this study, structural variations of MPs that occur naturally in bacterial peptidoglycan were investigated for somnogenic activity. Monomeric and dimeric MPs were isolated and purified from Neisseria gonorrhoeae and Actinomadura sp. strain R39. The structures of these MPs were verified by fast atom bombardment mass spectroscopy and tandem mass spectroscopy. After intracerebroventricular administration of MPs, electroencephalograms and brain temperatures of rabbits were recorded for 6 h and were analyzed to determine durations of slow-wave sleep, rapid-eye-movement sleep, and wakefulness. The 6-0 acetylation of muramic acid enhanced the somnogenic effects of certain monomeric MPs relative to their non-0-acetylated (but otherwise identical) counterparts. Two monomeric MPs containing an unsubstituted amide (i.e., Iso-Gln) were inactive, thus confirming previous results showing that amidation of a variety of MPs can block somnogenic activity. Two peptide-cross-linked MP dimers tested had no effect on slow-wave sleep, although a third peptide-cross-linked MP containing a 1,6-anhydro muramyl end on one of its monomeric subunits, a structure that enhances somnogenic potency of un-cross-linked monomers, was somnogenic. Two dimers connected by glycosidic bonds and containing an Iso-Gln moiety were inactive. Two other glycosidically linked dimers that also contained an Iso-Gln moiety, but were of lower molecular weight, were somnogenic. In summary, 6-0 acetylation of muramic acid in somnogenic MPs enhances activity, and as a class, peptide-linked dimeric MPs tend to be less active than their constituent monomers.
A sleep-promoting substance, called factor S, accumulates in cerebrospinal fluid (CSF) during prolonged wakefulness (10) . Intracerebroventricular administration of factor S into healthy animals induces a prolonged enhancement of slowwave sleep (SWS) (18) . Substances with indistinguishable physical, chemical, and biological properties were later obtained from brain and urine in sufficient amounts to identify them as muramyl peptides (MPs) (23, 28) . The structure of the most active component is N-acetylglucosaminyl-1 ,6-anhydro-N-acetylmurmyl-alanyl--y-glutamyldiaminopimelyl-alanine (NAG-1,6-anhydro-NAM-Ala-y-GluDap-Ala) (called urinary factor S [FSu] ) (28) . Coincidentally, the identical substance had been previously identified in supernatants of growing Neisseria gonorrhoeae (35) and in enzymatic digests of Escherichia coli and gonococcal peptidoglycan (13, 35, 36) and was ultimately pufified to homogeneity from digests of gonococcal peptidoglycan (29) . These findings and the fact that there are no known pathways in mammals for the biosynthesis of certain components of MPs have led to the postulate that the MPs found in mammalian tissue are of bacterial origin (1, 16) .
Peptidoglycan is a large netlike molecule consisting of sugar chains of alternating N-acetylglucosamine and Nacetylmuramic acid. These chains are interconnected by short peptides (34) . When peptidoglycan is digested by cell wall lytic enzymes, monomeric MPs are produced and, depending on the chemical structure of the peptidoglycan of the specific strain investigated, different amounts of di-, tri-, and polymeric MPs are formed. Two types of dimeric MPs can be expected, dimers connected via glycosidic linkage and dimers connected via peptide bonds.
A variety of structurally different MPs, either derived from bacterial cell walls or chemically synthesized, have been investigated for their structure-somnogenic activity relationships (24) (25) (26) . The smallest somnogenic MP tested so far was muramyl dipeptide (N-acetylmuramyl-L-alanyl-Disoglutamine [NAM-L-Ala-D-Iso-Gln]), although muramyl dipeptide was at least 50-fold less potent than the naturally occurring FSu. The main structural variations known to influence the somnogenic activity of MPs are as follows. (i) The steric conformation of L-Ala-D-Iso-Gln as in muramyl dipeptide is crucial; e.g., NAM-D-Ala-D-Iso-Gln is inactive (24) . ( ii) The 1,6-anhydro structure of muramic acid, as is present in FSu, greatly enhances potency for promoting SWS; e.g., 1 pmol of FSu is sufficient to promote SWS, whereas the corresponding hydrated form of FSu is inactive at 10 times this dose (25) . (iii) Conversion of certain carboxyl groups, e.g., the y-carboxyl of Iso-Gln in muramyl dipeptide, to unsubstituted amides completely blocks somnogenic activity (26) . (iv) The presence of N-acetylglucosamine (NAG) in a 3-1,4-glycosidic linkage to the carbon 4 of N-acetylmuramic acid (NAM) is not essential for SWSpromoting activity (25) .
In the present study, we have investigated several substances containing additional structural variations that occur naturally in bacterial cell walls: 6-0-acetyl substitution of NAM and several structurally different MP dimers. The 0 acetylation of carbon 6 (C-6) of muramic acid is known to (30, 31) and were obtained by an enzymatic degradation of the cell wall as previously described (30, 31) . All MPs were purified by reversed-phase high-pressure liquid chromatography (29) . Their protonated molecular weights, (M+H)+, were determined by fast atom bombardment (FAB) mass spectrometry (MS), and their covalent structures were verified by tandem mass spectrometry (MS/MS) as described before (29) . Sleep assays. Adult male New Zealand White rabbits were provided with permanent electroencephalographic (EEG) recording electrodes, a brain thermistor, and a guide tube to a lateral cerebral ventricle as previously described (21) . At least 10 days were allowed for recovery from the surgery before experiments were performed. The rabbits were housed in individual cages at 21 + 2°C on a 12-h dark-12-h light cycle. Before experiments, the rabbits were adapted to experimental cages overnight. Food and water were available ad libitum at all times. EEGs, average EEG slow-wave (0.5 to 3.5 Hz) amplitudes, brain temperatures, and movement of the rabbits were recorded for 6 h after injections, as previously described (19) . Colonic temperatures were taken immediately before the intracerebroventricular injection and after the recording (19) . EEG records were visually scored in 12-s epochs for amounts of wakefulness, SWS, and rapideye-movement sleep (REMS), as previously described (19) .
Solutions of the MPs in 0.05 or 0.1 ml of artificial CSF (19) were injected intracerebroventricularly over 2 and 5 min, respectively, 3 h after the onset of the light cycle at 0900 h. One to three doses of each substance were tested; in most cases, four rabbits were used for each dose tested. Control recordings were obtained from the same rabbits by injecting artificial CSF alone; thus, a within-subject matched-pairs experimental design was used. Treated groups were compared with their own controls with a nonparametric two-way analysis of variance (Friedman test).
RESULTS
Structure determination. The molecular weights and chemical structures of the substances tested, determined by FAB MS and MS/MS. respectively, are depicted in Table 1 . The structures of several of the compounds in Table 1 (Fig. 2) . Another facet of temperature regulation was unaffected by any of the MPs tested. For example, during entry into SWS the regulated decreases in brain temperature (12) and, after the onset of REMS, the increases in brain temperatures that normally occur (19) persisted in the MP-treated animals despite, in some cases, the simultaneous occurrence of fever (data not shown). Although not quantified, the behavior of animals receiving MPs remained normal, i.e., the animals continued to eat, drink, and groom when awake. Animals continued to oscillate between various states of vigilance, although, as noted above, duration of these states was altered by some of the MPs tested. Rabbits responded normally to handling at the end of the recording period.
Structure-activity relationships. We tested three pairs of MPs that differed within each pair only in the presence (or absence) of an 0-acetyl substitution at the C-6 position of the muramic acid residue (6-O-acetyl somnogenic activity) and a free amide on the a-carbon of its Glu residue. This substance had little effect on sleep; however, it induced a significant increase of colonic temperature when 100 pmol was injected. A similar substance that was amidated but lacked the 1,6-anhydro structure (substance 8 [ Table 2 ]) had no influence on sleep or temperature.
Three different MP dimers in which the monomeric subunits were connected via peptide cross-linkage were tested (substances 9, 10, and 11 [ Table 1 ]). One of these consisted of two NAG-NAM-Ala-y-Glu-Dap-Ala molecules connected via a peptide linkage from the e-amino group of Dap on one monomer to the COOH group of the terminal Ala of the other monomer (no. 9). This MP dimer had no SWSpromoting activity, even at the highest dose tested (100 pmol), although the corresponding monomer (no. 4) did enhance SWS at 100 pmol. The addition of a terminal alanine to the carboxyl end of one of the monomeric subunits of dimeric compound 9 (to yield compound 10) did not reverse the lack of somnogenic activity. However, the introduction of a 1,6-anhydro substitution in one of the NAM moieties in MP dimer 9 (to produce dimer 11) rendered this substance somnogenic and pyrogenic at 100 pmol. Further, dimer 11 was pyrogenic after injection of the lower dose of 10 pmol.
Four MP dimers in which the monomeric subunits were connected by 3-1,4-glycosidic bonds were also tested. Two of the glycosidically linked dimers (no. 12 and 13 [ Table 1 Table 1 ]) on sleep and brain temperature of rabbits. EEGs and brain temperatures were recorded for 6 h after injection of the sample in artificial CSF (0 or in artificial CSF alone (0). To assess brain temperatures, the signal of an implanted thermistor was calibrated by using colonic temperatures taken immediately before and after the recording, as previously described (22) were inactive, as were the corresponding monomers from which they were composed, i.e., no. 7 and 8 for 12 and no. 8 for 13. Two others of these MP dimers (no. 14 and 15 [ Table 1 ]) were found to be somnogenic and pyrogenic after injection of 100 pmol. One of these, no. 14, is compound 8 modified by the addition of a disaccharide moiety.
DISCUSSION
It was previously established that the substitution of NAM in muramyl peptides with an internal 1,6-anhydro bond strongly enhances the somnogenic effects of these MPs (25) .
The data presented here demonstrate that another manipulation on the C-6 atom of muramic acid, the substitution with acetic acid in an ester bond (6-0-acetyl), also enhances SWS-promoting activity. This effect, however, was not as pronounced as that observed with the 1,6-anhydro form of muramic acid. Both of these substitutions on the NAM residue lessen the polarity of the molecule. Additionally, the formation of the 1,6-anhydro bond changes the spatial conformation of the sugar ring dramatically (G. Barnickel, personal communication). Both structural variations, the 1,6-anhydro and 6-0-acetyl substitutions, are known to occur in bacteria. Whether these spatial arrangements and/or changes in polarity of the NAM are responsible for the variations in somnogenic effect remains to be determined.
Since the ester bond of the 0-acetyl group is relatively weak, it is tempting to speculate that this site may be enzymatically altered in vivo to regulate SWS-promoting activity of MPs. However, 0-acetyl groups reduce the degradability of the bacterial cell walls by lysozyme (3, 5, 14) , the best-characterized enzyme known to digest bacterial cell walls, and by intact polymorphonuclear leukocytes and macrophages (39) . Furthermore, the degree of 0 acetylation is elevated when bacteria are allowed to enter the stationary phase of growth or when they are treated with certain bacteriostatic antibiotics (6, 14, 15, 33) . Some P-lactam antibiotics, on the other hand, lower the contents of 0-acetyl groups on cell walls (2, 27, 32) .
Compound 7, which contains an unsubstituted amide of the a-carboxyl portion of its Glu residue, was inactive, thus confirming earlier findings concerning the importance of amidation of monomeric MPs on their somnogenic activity. Thus, one of the most active substances yet tested, NAG-(1,6-anhydro)NAM-Ala-y-Glu-Dap-Ala, which is active at 1 pmol (25) , is somnogenically inactive at a dose of 100 pmol upon substitution of Iso-Gln for -y-Gln (compound 7). Similarly, we previously showed that the somnogenically inactive diamide NAG-(1,6-anhydro)NAM-Ala-Iso-Gln-Dap (NH2)-Ala-Ala could be converted to an active compound if one of the amide groups was removed by mild acid hydrolysis (20) . At *~~~~_ dimers were hydrolyzed in vivo into their monomeric constituents remains unknown. MPs alter cytokine production in a variety of cell types (for a review, see reference 7). The most extensively studied cytokine in regard to sleep is interleukin-1 (IL-1). The effects of IL-1 on sleep are similar to those described for MPs, and it is hypothesized that MPs elicit their somnogenic actions via a step involving enhanced IL-1 production. Also consistent with this hypothesis is the observation that other substances which enhance IL-1 production, i.e., endotoxin and its lipid A moiety (21) and poly(rI)-poly(rC) (22) , also enhance SWS. IL-1 can be produced by glial cells (11) . IL-1 1-like immunoreactive neurons have been described elsewhere (4) . Furthermore, IL-1 P-mRNA and IL-1 receptors are found in the healthy brain (8, 9 
